Key statistics
On Thursday, Inhibikase Therapeutics Inc (IKT:NAQ) closed at 1.64, 23.31% above the 52 week low of 1.33 set on Nov 03, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.69 |
|---|---|
| High | 1.70 |
| Low | 1.61 |
| Bid | 1.57 |
| Offer | 1.74 |
| Previous close | 1.71 |
| Average volume | 895.93k |
|---|---|
| Shares outstanding | 120.90m |
| Free float | 111.22m |
| P/E (TTM) | -- |
| Market cap | 206.74m USD |
| EPS (TTM) | -1.15 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
More ▼
Announcements
- Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
- Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
- Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
- Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
- Inhibikase Announces Expansion of Senior Leadership Team
More ▼
